Trial site
PsychoLine s.r.o.
Rimavska Sobota, 97901, SlovakiaEU-13 widening countryNot linked to an institution yet
- 6running trials
- 7closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 24 trials
- Phase 2/31 trial
- Status
- Completed7 trials
- Recruiting5 trials
- Active, not recruiting1 trial
- Lead sponsor
- Neurocrine Biosciences3 trials
- Seaport Therapeutics2 trials
- Boehringer Ingelheim International GmbH1 trial
- HMNC Holding GmbH1 trial
- Intra-Cellular Therapies, Inc.1 trial
- and 5 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source
Completed
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
2022-502233-25-00· Phase 3· Neurocrine Biosciences Inc.· Source
Completed
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· Phase 3· Janssen Cilag International· Source
Completed
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373· Phase 2/3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study
2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source
Completed
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157· Phase 3· Neurocrine Biosciences· Source
Completed
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.
NCT04464564· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source
Report an error